We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+16.29%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$8.82B
AUM Growth
+$974M
Cap. Flow
+$85.6M
Cap. Flow %
0.97%
Top 10 Hldgs %
37.09%
Holding
149
New
20
Increased
26
Reduced
29
Closed
13

Top Buys

Rank Stock Value
1
CNC icon
Centene
CNC
+$111M
2
AGN.PRA
Allergan plc
AGN.PRA
+$73.1M
3
MRK icon
Merck
MRK
+$69.9M
4
AET
Aetna Inc
AET
+$63.6M
5
VTRS icon
Viatris
VTRS
+$52.4M

Top Sells

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$148M
2
NBIX icon
Neurocrine Biosciences
NBIX
+$72.3M
3
AGN
Allergan plc
AGN
+$68.1M
4
ISRG icon
Intuitive Surgical
ISRG
+$67.6M
5
SHPG
Shire pic
SHPG
+$53.4M

Sector Composition

Rank Sector Weight
1 Healthcare 92.96%
2 Financials 2.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BMRN icon
26
BioMarin Pharmaceuticals
BMRN
$12B
$112M 1.27%
1,274,100
– –
CRVS icon
27
Corvus Pharmaceuticals
CRVS
$1.11B
$112M 1.27%
5,379,349
– –
JNJ icon
28
Johnson & Johnson
JNJ
$643B
$110M 1.25%
884,600
+26,600
+3% +$3.18M
BMY icon
29
Bristol-Myers Squibb
BMY
$130B
$104M 1.18%
1,911,000
+417,500
+28% +$22.9M
SGYP
30
DELISTED
Synergy Pharmaceuticals, Inc Common Stock
SGYP
$98.6M 1.12%
21,153,343
+2,911,945
+16% +$16.9M
THC icon
31
Tenet Healthcare
THC
$22.2B
$94.8M 1.07%
5,352,000
+1,635,300
+44% +$30.3M
GKOS icon
32
Glaukos
GKOS
$9.04B
$89.3M 1.01%
1,741,700
-438,300
-20% -$19.1M
INSM icon
33
Insmed
INSM
$22.6B
$84.2M 0.95%
4,810,905
-490,900
-9% -$7.57M
PBYI icon
34
Puma Biotechnology
PBYI
$404M
$83.5M 0.95%
2,245,925
-29,900
-1% -$1.09M
TMO icon
35
Thermo Fisher Scientific
TMO
$215B
$82.1M 0.93%
534,200
-265,300
-33% -$40.5M
BOLD
36
DELISTED
Audentes Therapeutics, Inc
BOLD
$81.8M 0.93%
4,801,638
– –
VRAY
37
DELISTED
ViewRay, Inc.
VRAY
$80.5M 0.91%
9,458,567
+330,577
+4% +$1.8M
ASND icon
38
Ascendis Pharma A/S
ASND
$16.8B
$76.1M 0.86%
2,717,315
– –
MGLN
39
DELISTED
Magellan Health Services, Inc.
MGLN
$75.2M 0.85%
1,088,727
+287,127
+36% +$21M
AGN.PRA
40
DELISTED
Allergan plc
AGN.PRA
$74.8M 0.85%
+88,200
New +$73.1M
LOXO
41
DELISTED
Loxo Oncology, Inc
LOXO
$72.7M 0.82%
1,728,000
– –
AERI
42
DELISTED
Aerie Pharmaceuticals
AERI
$67.8M 0.77%
1,496,000
– –
MNK
43
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
$65.6M 0.74%
1,472,700
– –
INSY
44
DELISTED
Insys Therapeutics, Inc.
INSY
$63.8M 0.72%
6,071,440
– –
MDT icon
45
Medtronic
MDT
$113B
$61.8M 0.7%
766,600
– –
GWPH
46
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$57.6M 0.65%
475,900
+79,300
+20% +$9.73M
EGRX
47
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
$55.7M 0.63%
671,000
– –
ACHN
48
DELISTED
Achillion Pharmaceuticals
ACHN
$55.2M 0.63%
13,107,200
– –
ILMN icon
49
Illumina
ILMN
$29.4B
$54.9M 0.62%
330,913
+143,611
+77% +$22.6M
GILD icon
50
Gilead Sciences
GILD
$166B
$54.4M 0.62%
800,900
-254,200
-24% -$17.9M
1
2
3 4 5

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q1 2017 Portfolio in Review

As of Q1 2017, OrbiMed held 149 positions worth $8.82B, up 12% from $7.85B the previous quarter. Its ten largest holdings account for 37% of the portfolio.

OrbiMed's Q1 2017 filing shows 20 new, 26 increased, 29 reduced and 13 closed positions. Its largest new stake was Centene: 3,311,400 shares worth $118M. The largest sale was Amgen, an estimated $148M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 94% a quarter earlier, followed by Financials.

  • OrbiMed's largest Q1 2017 buy was Centene: 3,311,400 shares worth $118M.
  • OrbiMed added most to Merck in Q1 2017, an estimated $69.9M increase.
  • OrbiMed's biggest Q1 2017 reduction was Amgen, cutting an estimated $148M.
  • OrbiMed fully exited Molina Healthcare in Q1 2017, selling an estimated $26.9M.
  • OrbiMed's ten largest holdings make up 37% of its $8.82B portfolio in Q1 2017.
  • OrbiMed opened 20 new positions and closed 13 in Q1 2017.
  • OrbiMed's portfolio value rose 12% quarter-over-quarter to $8.82B.

Based on OrbiMed's 13F filing for Q1 2017, filed 15 May 2017.